2021
70-OR: Evaluation of the Omnipod 5 Automated Insulin Delivery System in Very Young Children with Type 1 Diabetes (T1D)
SHERR J, BODE B, FORLENZA G, LAFFEL L, BROWN S, BUCKINGHAM B, CRIEGO A, DESALVO D, MACLEISH S, HANSEN D, LY T. 70-OR: Evaluation of the Omnipod 5 Automated Insulin Delivery System in Very Young Children with Type 1 Diabetes (T1D). Diabetes 2021, 70 DOI: 10.2337/db21-70-or.Peer-Reviewed Original ResearchDiabetes careDiabetic ketoacidosisStandard therapySevere hypoglycemiaSpeakers bureauEli LillyYoung childrenPrimary safety outcomePrimary effectiveness outcomeSerious adverse eventsAdvisory PanelLexicon PharmaceuticalsDaily dose requirementsType 1 diabetesNovo NordiskBoehringer Ingelheim PharmaceuticalsMannKind CorporationPermissive hyperglycemiaBaseline characteristicsHybrid closed-loop systemT1D durationAdverse eventsGlucose targetsEfficacy analysisInsulin delivery systems
2019
926-P: Frequency of Hypoglycemia by Gender in Healthy Individuals without Diabetes—Not So Different After All
DUBOSE S, LI Z, SHAH V, SHERR J, TAMBORLANE W, BERGENSTAL R, BECK R. 926-P: Frequency of Hypoglycemia by Gender in Healthy Individuals without Diabetes—Not So Different After All. Diabetes 2019, 68 DOI: 10.2337/db19-926-p.Peer-Reviewed Original ResearchHealthy individualsMedtronic MiniMedFrequency of hypoglycemiaDuration of hypoglycemiaEli LillyPercentage of participantsHelmsley Charitable TrustNon-Hispanic whitesBoehringer Ingelheim PharmaceuticalsRace/ethnicityTakeda Pharmaceutical Company LimitedNondiabetic childrenSanofi USAdvisory PanelMean HbA1cHypoglycemic eventsKidney diseaseMulticenter studyDiabetes careMore hypoglycemiaHarry B. Helmsley Charitable TrustPercentage of timeAverage glucoseDiabetesHypoglycemia
2018
Risk Factors for Cardiovascular Disease (CVD) in Adults with Type 1 Diabetes (T1D)
MEHTA S, WU M, FOSTER N, POP-BUSUI R, KATZ M, CRANDALL J, BACHA F, NADEAU K, LIBMAN I, HIERS P, MIZOKAMI-STOUT K, DIMEGLIO L, SHERR J, PRATLEY R, AGARWAL S, SNELL-BERGEON J, CENGIZ E, POLSKY S, SHAH V. Risk Factors for Cardiovascular Disease (CVD) in Adults with Type 1 Diabetes (T1D). Diabetes 2018, 67 DOI: 10.2337/db18-15-lb.Peer-Reviewed Original ResearchCVD risk factorsIncident cardiovascular diseaseRisk factorsCardiovascular diseaseDiabetic nephropathyT1D Exchange Clinic RegistryTraditional CVD risk factorsEli LillyPediatric Diabetes ConsortiumBlood pressure medicationsIschemic heart diseaseImportant risk factorType 1 diabetesNon-fatal eventsNational InstituteYears of ageBoehringer Ingelheim PharmaceuticalsAdvisory PanelEisai Inc.MannKind CorporationDiabetes durationComposite outcomeHeart failureClinic registryContemporary cohortIncreased HbA1c Variability May Shorten Time to Microalbuminuria Development in Type 1 Diabetes (T1D)
CLEMENTS M, WU M, FOSTER N, LAFFEL L, SHAH V, VENDRAME F, KINGMAN R, ALONSO G, CARLSON A, DESALVO D, BUCKINGHAM B, SHERR J, BENJAMIN R, EYTH E, DUBOSE S. Increased HbA1c Variability May Shorten Time to Microalbuminuria Development in Type 1 Diabetes (T1D). Diabetes 2018, 67 DOI: 10.2337/db18-26-lb.Peer-Reviewed Original ResearchRisk of microalbuminuriaSD HbA1cDiabetes careT1D Exchange Clinic RegistryShorter diabetes durationSpeakers bureauType 1 diabetesAge of diagnosisEli LillyBoehringer Ingelheim PharmaceuticalsAdvisory PanelMannKind CorporationMicroalbuminuria developmentSanofi USDiabetes durationMean HbA1cT1D durationRenal diseaseClinic registryRegistry enrollmentClinic visit recordsT1D populationMedian numberMicroalbuminuriaDiabetes Institute